Cue Biopharma, Inc.
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable precision immunotherapies designed to selectively modulate disease-relevant T cells. Its core Immuno-STAT platform is being applied to oncology and autoimmune disease, with most of the company’s activity still centered on research, development, and partnering rather than product sales.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInternal drug candidates in oncology and autoimmune disease, including CUE-101, CUE-102, CUE-401 and the CUE-500 series.
Milestone, research, and license revenue from partnered programs such as BI, IMSCP, LG Chem, Ono, and Merck.
Customers
Cue Biopharma does not sell approved drugs commercially; its current counterparties are pharmaceutical and biotechnology partners that fund or co-develop programs. In practice, the “customers” are collaboration partners, licensing counterparties, and eventually healthcare providers and patients if any candidate reaches commercialization. The company’s oncology and autoimmune assets are aimed at unmet-need indications where partners value differentiated biology and clinical de-risking.
Large pharmaceutical companies that license or co-develop programs such as CUE-501 to access differentiated biology and share development risk.
Smaller biotech partners that fund research, option rights, or regional development in exchange for access to the platform.
Future end users for CUE-101/CUE-102 if approved, especially in HPV+ head and neck cancer and other solid tumors.
Potential future users of CUE-401 and CUE-500 series therapies designed to restore immune balance.
Strategy
The company’s near-term strategy is to advance its most promising internal assets while using partnerships to extend capital and broaden development capacity. Management has highlighted CUE-401 as a priority IND candidate and is actively seeking collaborations for oncology assets such as CUE-101 and CUE-102, while the BI deal expands the partnered pipeline around CUE-501. This approach is meant to preserve optionality, reduce single-asset dependence, and improve the odds of eventual commercialization.
A new IND-stage autoimmune asset can refresh the pipeline and create a near-term value catalyst.
Partnering reduces funding burden and helps validate the platform across oncology and autoimmune disease.
A diversified pipeline lowers dependence on any single clinical outcome and increases partnering leverage.
Geography
Cue Biopharma is headquartered in the United States and conducts its core R&D there, while its business model depends on global partnering for development and eventual commercialization. The company’s disclosed collaboration structure includes worldwide rights in some agreements, so future economics may be spread across multiple regions even though the current operating base is U.S.-centric. Its risk profile also reflects international supply-chain and tariff exposure, including reliance on contract manufacturers and service providers that may operate in China.
Risks
Cue Biopharma remains a development-stage company with recurring losses and no commercial product revenue, so financing and going-concern risk are central. Clinical, regulatory, and partnering execution risk is high because value depends on successful trial data, IND filings, and counterparties continuing to fund or advance programs. The company also faces supply-chain and tariff exposure, plus Nasdaq listing risk if it cannot maintain compliance.
- Going-concern and liquidity riskImpact: CriticalLikelihood: High
The company has recurring losses and depends on external capital and collaboration receipts to fund operations.
Exposure: Development-stage operations and R&D spend
- Clinical development failureImpact: HighLikelihood: High
Pipeline value depends on positive efficacy, tolerability, and regulatory progress for candidates like CUE-101, CUE-102, and CUE-401.
Exposure: Lead oncology and autoimmune programs
- Partner concentration and termination riskImpact: HighLikelihood: High
Collaboration revenue is tied to a small number of agreements and can stop if partners terminate or slow work.
Exposure - Supply-chain and tariff disruptionImpact: MediumLikelihood: High
Development and manufacturing may rely on external providers, including China-linked suppliers, which can be affected by trade restrictions.
Exposure - Nasdaq listing complianceImpact: MediumLikelihood: High
Failure to maintain minimum bid price or other requirements could lead to delisting and reduced capital access.
Exposure: Public equity financing
Accounting
Judgemental itemsRevenue from BI, IMSCP, LG Chem, Ono and Merck depends on contract milestones and services performed, creating period-to-period volatility.
Impact: Affects reported revenue and comparability across quarters
Most costs are expensed as incurred, and management does not allocate them by project, which obscures program economics.
Impact: Affects operating loss and makes asset-level profitability hard to assess
Recurring losses and limited cash runway require management judgment about future funding and operating continuity.
Impact: Can influence disclosure, valuation, and investor perception
Partner agreements can create short- and long-term liabilities and require judgment on timing of recognition.
Impact: Affects balance sheet obligations and revenue timing
Similar listed companies
Publicly listed companies with a comparable business focus.
Estrella Immunopharma, Inc.
ESLAW · Biological Products, (No Diagnostic Substances)
BioVie Inc
BIVIW · Pharmaceutical Preparations
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Immunic, Inc
IMUX · Pharmaceutical Preparations
Last updated: 24/09/2026